Evaluation of baseline fracture risk in younger postmenopausal women with breast cancer using different risk assessment methods

Evaluation of baseline fracture risk in younger postmenopausal women with breast cancer using different risk assessment methods - EPI -OSt

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00016907

Enrollment

343

Registered

2019-03-07

Start date

2017-08-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

M81.00

Interventions

Group 1: The intervention group receives a bone density measurement as a routine examination within the first 3 months after the start of aromatase inhibitor therapy. In addition, the FRAX (Fracture R

Eligibility

Sex/Gender

Female

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Study population: postmenopausal women between 50-59 years of age who receive aromatase inhibitor therapy due to hormone receptor-positive breast cancer and receive a bone density measurement within the first 3 months. Control group: healthy, postmenopausal women between 50-59 years of age receiving bone density measurement.

Exclusion criteria

Exclusion criteria: Women younger than 50 or older than 59 years, premenopausal women, women who receive a specific antiosteoporotic therapy, women who do not want to give informed consent, women with a BMI>30kg/m² or a BMI <15 kg/m², because in these cases an exact TBS measurement is not possible.

Design outcomes

Primary

Measure	Time frame
All patients receive a structured questionnaire in which the FRAX criteria and the most important risk factors of osteoporosis are assessed. It will be investigated whether patients with breast cancer show a difference in bone density and thus in fracture risk compared to healthy women. The differences in FRAX score, TBS and TBS adjusted FRAX score are measured within a period of 3 months after the start of aromatase inhibitor therapy.	—

Measure

Time frame

All patients receive a structured questionnaire in which the FRAX criteria and the most important risk factors of osteoporosis are assessed. It will be investigated whether patients with breast cancer show a difference in bone density and thus in fracture risk compared to healthy women. The differences in FRAX score, TBS and TBS adjusted FRAX score are measured within a period of 3 months after the start of aromatase inhibitor therapy.

—

Countries

Austria

Contacts

Public ContactChristian Pirich

Univ.Klinik für Nuklearmedizin

christian.pirich@salk.at004357 2550

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026